Our working group reviewed the prognostic significance of a select group of contemporary molecular biomarkers with strong pre-clinical evidence including translocation subtype and mechanism of formation; STAG2 loss and TP53 pathogenic mutations; copy number variants; tumor mutational burden (TMB); circulating tumor DNA (ctDNA); and germline DNA defects (Fig. 1). This evidence concerns the gene STAG2 and neoplasm.